Some of you may have already seen this, but here is the schedule for the Oncolytics Biotech related presentations with excerpts from the abstracts.
Abstract Number: 906
Session Title: Therapeutic Implications of Oncogenic Pathways 1
Presentation Title: Replication of mutant strains of oncolytic reovirus in different cell lines
Presentation Start/End Time: Sunday, Apr 13, 2008, 1:00 PM - 5:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Poster Section: 5
Poster Board Number: 17
Author Block: Guy Lemay. Universite de Montreal, Montreal, QC, Canada
Murine NIH-3T3 cells are poorly infected by mammalian reovirus but support productive infection upon cell transformation by H-Ras(G12V), leading to the idea that reovirus could be used as an “oncolytic” virus.
Altogether, our data thus support the idea that cellular factors affecting reovirus replication are complex and linked to pathways leading to cellular transformation. We further suggest that viral strains should be chosen or manipulated to optimize their oncolytic potential. The σ3 protein appears as the most likely viral factor to be involved in modulating the virus’ ability to replicate in different normal or transformed cell types.
See the original page here.
Abstract Number: 3751
Session Title: Pediatric Cancer 3
Presentation Title: Radiation in combination with Reolysin for pediatric sarcomas
Presentation Start/End Time: Tuesday, Apr 15, 2008, 8:00 AM -12:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Poster Section: 15
Poster Board Number: 12
Author Block: Pooja Gidwani, Wendong Zhang, Laibin Liu, Chandan Guha, E Anders Kolb. Albert Einstein College of Medicine, Bronx, NY, A I duPont Children's Hospital, Wilmington, DE
With advances in the scientific knowledge of molecular mechanisms of cancer and viral replication, oncolytic viruses have emerged as an interesting potential therapeutic strategy for several human cancers.
Conclusions: Our data suggests that the combination of reovirus and radiation therapy has enhanced efficacy than either of the individual treatments alone in pediatric sarcomas. This is especially interesting since reovirus was administered systemically instead of intratumorally suggesting the potential use of this treatment modality even in metastatic and hard to reach tumors. Our data warrants further testing of this combination in clinical trials.
See the original page here.
Abstract Number: 4971
Session Title: Novel Genomic Approaches, Drugs, Targets, and Strategies
Presentation Title: Targeting multiple myeloma with oncolytic viral therapy
Presentation Start/End Time: Tuesday, Apr 15, 2008, 4:40 PM - 4:55 PM
Location: Room 30A-C, San Diego Convention Center
Author Block: Chandini M. Thirukkumaran, Zhong-Qiao Shi, Jason Spurell, Douglas Stewart, Joanne Luider, Don Morris. Tom Baker Cancer Centre, Calgary, AB, Canada, Calgary Laboratory Services, Calgary, AB, Canada
In the present study we investigate 1) The oncolytic ability of reovirus against a larger number of MM cell lines and ex vivo patient specimens in order to assess MM sensitivity to reovirus in a community population, 2) Reovirus purging efficacy in a murine model of transplantation.
Conclusions: The sensitivity of reovirus towards MM and its lack of effect human stem cells highlight the potential of reovirus as a purging agent during autologous hematopoietic stem cell transplants for MM. The SCID/NOD model system used in the present study appears suitable for evaluating reovirus purging efficacy in vivo. Currently, we are in the process of studying reovirus purging efficacy in vivo and its purging capacity of ex vivo MM patient tumor in order to generate data for a future phase I clinical trial.
See the original page here.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment